×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ALKS – alkermes plc - ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ALKS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/16
07:00 am
alks
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
Low
Report
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
4/14
07:00 am
alks
Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry
Low
Report
Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry
4/9
12:18 pm
alks
Alkermes (ALKS) had its price target raised by Bank of America Corporation from $34.00 to $36.00. They now have a "neutral" rating on the stock.
Low
Report
Alkermes (ALKS) had its price target raised by Bank of America Corporation from $34.00 to $36.00. They now have a "neutral" rating on the stock.
4/1
07:00 am
alks
Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
Low
Report
Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
3/26
05:49 am
alks
Alkermes (ALKS) was upgraded by Truist Financial Corporation to "strong-buy".
Medium
Report
Alkermes (ALKS) was upgraded by Truist Financial Corporation to "strong-buy".
3/24
09:17 am
alks
Alkermes (ALKS) had its price target lowered by Piper Sandler from $45.00 to $43.00. They now have an "overweight" rating on the stock.
Low
Report
Alkermes (ALKS) had its price target lowered by Piper Sandler from $45.00 to $43.00. They now have an "overweight" rating on the stock.
3/24
07:10 am
alks
Alkermes (ALKS) was downgraded by Zacks Research from "hold" to "strong sell".
Low
Report
Alkermes (ALKS) was downgraded by Zacks Research from "hold" to "strong sell".
3/17
05:45 pm
alks
Alkermes CEO Pops Calls 2026 a “Really Exciting Year” as Orexin Agonists Near Narcolepsy Launch [Yahoo! Finance]
Low
Report
Alkermes CEO Pops Calls 2026 a “Really Exciting Year” as Orexin Agonists Near Narcolepsy Launch [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
2/25/2026
07:05 am
ALKS
alkermes plc - ordinary shares
MISS
Report
-4.5%
alkermes plc - ordinary shares
10/28/2025
07:00 am
ALKS
alkermes plc - ordinary shares
BEAT
Report
-1.1%
alkermes plc - ordinary shares
7/29/2025
07:00 am
ALKS
alkermes plc - ordinary shares
BEAT
Report
4.5%
alkermes plc - ordinary shares
5/1/2025
07:00 am
ALKS
alkermes plc - ordinary shares
MISS
Report
6.1%
alkermes plc - ordinary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/13
05:10 pm
alks
Form 4 Alkermes plc. For: Apr 11 Filed by: Lurker Nancy
Low
Report
Form 4 Alkermes plc. For: Apr 11 Filed by: Lurker Nancy
4/6
07:57 pm
alks
Form 4 Alkermes plc. For: Apr 06 Filed by: Gaffin David Joseph
Low
Report
Form 4 Alkermes plc. For: Apr 06 Filed by: Gaffin David Joseph
4/6
05:17 pm
alks
Form ARS Alkermes plc. For: Dec 31
Medium
Report
Form ARS Alkermes plc. For: Dec 31
4/6
05:06 pm
alks
Form DEF 14A Alkermes plc. For: May 20
Medium
Report
Form DEF 14A Alkermes plc. For: May 20
4/6
04:17 pm
alks
Form 144 Alkermes plc. Filed by: Gaffin David Joseph
Medium
Report
Form 144 Alkermes plc. Filed by: Gaffin David Joseph
4/1
06:59 pm
alks
Form 4 Alkermes plc. For: Apr 01 Filed by: Hopkinson Craig C.
Low
Report
Form 4 Alkermes plc. For: Apr 01 Filed by: Hopkinson Craig C.
4/1
04:14 pm
alks
Form 144 Alkermes plc. Filed by: Hopkinson Craig C.
Low
Report
Form 144 Alkermes plc. Filed by: Hopkinson Craig C.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/19
Alkermes to Present at the 9th Annual SVB Leerink Global Healthcare Conference
9.4%
3/13 Alkermes Plc (NASDAQ: ALKS) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 8.8%
7/29 Alkermes Announces Settlement With Amneal Over VIVITROL® Patent Dispute 7.5%
4/3 Form 4 Alkermes plc. For: Apr 02 Filed by: POPS RICHARD F 7.3%
2/18 Form 4 Alkermes plc. For: Feb 16 Filed by: LANDINE MICHAEL J 7.2%
7/30 Form 8-K Alkermes plc. For: Jul 26 6.0%
2/5 Form SC 13G/A Alkermes plc. Filed by: BlackRock Inc. 5.1%
12/4 Form CT ORDER Alkermes plc. 4.7%
9/10 Alkermes (ALKS) Investor Presentation - Slideshow [Seeking Alpha] 4.7%
10/23 Alkermes Plc (NASDAQ: ALKS) had its "hold" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $23.00 price target on the stock, down previously from $25.00. 4.6%
3/13 Alkermes Plc (NASDAQ: ALKS) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 8.8%
7/29 Alkermes Announces Settlement With Amneal Over VIVITROL® Patent Dispute 7.5%
4/3 Form 4 Alkermes plc. For: Apr 02 Filed by: POPS RICHARD F 7.3%
2/18 Form 4 Alkermes plc. For: Feb 16 Filed by: LANDINE MICHAEL J 7.2%
7/30 Form 8-K Alkermes plc. For: Jul 26 6.0%
2/5 Form SC 13G/A Alkermes plc. Filed by: BlackRock Inc. 5.1%
12/4 Form CT ORDER Alkermes plc. 4.7%
9/10 Alkermes (ALKS) Investor Presentation - Slideshow [Seeking Alpha] 4.7%
10/23 Alkermes Plc (NASDAQ: ALKS) had its "hold" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $23.00 price target on the stock, down previously from $25.00. 4.6%
TOP News Decliners
4/29
Form 10-Q Alkermes plc. For: Mar 31
-15.2%
7/25 Alkermes Plc Reports Second Quarter 2019 Financial Results -12.6%
2/13 Form 10-K Alkermes plc. For: Dec 31 -8.5%
3/19 Form 4 Alkermes plc. For: Mar 19 Filed by: POPS RICHARD F -7.3%
4/30 Alkermes Plc (NASDAQ: ALKS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock, down previously from $25.00. -6.9%
9/23 Form 4 Alkermes plc. For: Sep 19 Filed by: POPS RICHARD F -4.7%
10/23 Alkermes PLC (ALKS) Q3 2019 Earnings Call Transcript [The Motley Fool] -4.4%
5/13 Alkermes to Showcase Leadership in Schizophrenia With New Data Presentations at Upcoming Scientific Conferences -4.4%
7/18 Alkermes to Host Conference Call to Discuss Second Quarter 2019 Financial Results -4.2%
5/22 Form 8-K Alkermes plc. For: May 22 -4.0%
7/25 Alkermes Plc Reports Second Quarter 2019 Financial Results -12.6%
2/13 Form 10-K Alkermes plc. For: Dec 31 -8.5%
3/19 Form 4 Alkermes plc. For: Mar 19 Filed by: POPS RICHARD F -7.3%
4/30 Alkermes Plc (NASDAQ: ALKS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock, down previously from $25.00. -6.9%
9/23 Form 4 Alkermes plc. For: Sep 19 Filed by: POPS RICHARD F -4.7%
10/23 Alkermes PLC (ALKS) Q3 2019 Earnings Call Transcript [The Motley Fool] -4.4%
5/13 Alkermes to Showcase Leadership in Schizophrenia With New Data Presentations at Upcoming Scientific Conferences -4.4%
7/18 Alkermes to Host Conference Call to Discuss Second Quarter 2019 Financial Results -4.2%
5/22 Form 8-K Alkermes plc. For: May 22 -4.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: